Literature DB >> 20205057

Novel therapeutics for Alzheimer's disease: an update.

David J Bonda1, Hyun-Pil Lee, Hyoung-gon Lee, Avi L Friedlich, George Perry, Xiongwei Zhu, Mark A Smith.   

Abstract

As the most prevalent form of dementia worldwide, Alzheimer's disease (AD) continues to be a burden for patients and their families. In addition, with the global population of aged individuals increasing exponentially, AD represents a significant economic burden to society. The development of an effective approach for the treatment of AD is thus of major importance, as current treatment strategies are limited to agents that attenuate disease symptomatology without addressing the causes of disease. A considerable need exists for the development of an effective therapy to prevent, or at least delay, the progression of AD. Current hypotheses for the pathogenesis of AD are discussed in this review, with a particular emphasis on the implications of these hypotheses with respect to treatment strategies and preventive measures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205057      PMCID: PMC2931269     

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  159 in total

1.  Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation.

Authors:  Adam D Cash; Gjumrakch Aliev; Sandra L Siedlak; Akihiko Nunomura; Hisashi Fujioka; Xiongwei Zhu; Arun K Raina; Harry V Vinters; Massimo Tabaton; Anne B Johnson; Manuel Paula-Barbosa; Jesus Avíla; Paul K Jones; Rudy J Castellani; Mark A Smith; George Perry
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 2.  Kynurenines in neurodegenerative disorders: therapeutic consideration.

Authors:  Péter Klivényi; József Toldi; László Vécsei
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

3.  Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons.

Authors:  V V Grigorev; O A Dranyi; S O Bachurin
Journal:  Bull Exp Biol Med       Date:  2003-11       Impact factor: 0.804

Review 4.  Mitochondria and aging: a role for the permeability transition?

Authors:  M Crompton
Journal:  Aging Cell       Date:  2004-02       Impact factor: 9.304

5.  Mitochondria as a target for neurotoxins and neuroprotective agents.

Authors:  Sergey O Bachurin; Elena P Shevtsova; Elena G Kireeva; Gregory F Oxenkrug; Sergey O Sablin
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

6.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.

Authors:  Peter P Zandi; James C Anthony; Ara S Khachaturian; Stephanie V Stone; Deborah Gustafson; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; John C S Breitner
Journal:  Arch Neurol       Date:  2004-01

7.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors:  Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal:  Arch Neurol       Date:  2003-12

8.  Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.

Authors:  Osamu Ogawa; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Sci Aging Knowledge Environ       Date:  2002-10-16

Review 9.  Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease.

Authors:  Gjumrakch Aliev; Mark A Smith; Mark E Obrenovich; Jack C de la Torre; George Perry
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.

Authors:  Mar Pérez; Félix Hernández; Filip Lim; Javier Díaz-Nido; Jesús Avila
Journal:  J Alzheimers Dis       Date:  2003-08       Impact factor: 4.472

View more
  16 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

3.  Brain testosterone deficiency leads to down-regulation of mitochondrial gene expression in rat hippocampus accompanied by a decline in peroxisome proliferator-activated receptor-γ coactivator 1α expression.

Authors:  Takeshi Hioki; Shunya Suzuki; Megumi Morimoto; Tsuneo Masaki; Ryuichi Tozawa; Shigeru Morita; Takashi Horiguchi
Journal:  J Mol Neurosci       Date:  2013-09-05       Impact factor: 3.444

4.  Blood-CNS barrier, neurodegeneration and neuroprotection: recent therapeutic advancements and nano-drug delivery.

Authors:  Hari S Sharma
Journal:  J Neural Transm (Vienna)       Date:  2011-01       Impact factor: 3.575

5.  Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.

Authors:  Chun Xiao; Francesca J Davis; Balwantsinh C Chauhan; Kirsten L Viola; Pascale N Lacor; Pauline T Velasco; William L Klein; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  A mitochondrial etiology of Alzheimer and Parkinson disease.

Authors:  Pinar Coskun; Joanne Wyrembak; Samual E Schriner; Hsiao-Wen Chen; Christine Marciniack; Frank Laferla; Douglas C Wallace
Journal:  Biochim Biophys Acta       Date:  2011-08-16

7.  Phytic acid as a potential treatment for alzheimer's pathology: evidence from animal and in vitro models.

Authors:  Thimmappa S Anekonda; Teri L Wadsworth; Robert Sabin; Kate Frahler; Christopher Harris; Babett Petriko; Martina Ralle; Randy Woltjer; Joseph F Quinn
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 8.  Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!

Authors:  David J Bonda; Gang Liu; Ping Men; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-02       Impact factor: 4.388

Review 9.  Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass.

Authors:  David J Bonda; Xinglong Wang; Hyoung-Gon Lee; Mark A Smith; George Perry; Xiongwei Zhu
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

10.  NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.

Authors:  S Quraishe; C M Cowan; A Mudher
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.